 |
PDBsum entry 6ieb
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Structural protein/immune system
|
PDB id
|
|
|
|
6ieb
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
211 a.a.
|
|
|
|
|
|
|
|
|
|
|
207 a.a.
|
|
|
|
|
|
|
|
|
|
|
293 a.a.
|
|
|
|
|
|
|
|
|
|
|
182 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Structural protein/immune system
|
|
|
Title:
|
|
Structure of rvfv gn and human monoclonal antibody r15
|
|
Structure:
|
|
R15 h chain. Chain: h, e. Engineered: yes. R15 l chain. Chain: l, f. Engineered: yes. Nsmgngc. Chain: b, a. Synonym: glycoprotein n,gn.
|
|
Source:
|
|
Homo sapiens. Organism_taxid: 9606. Expressed in: homo sapiens. Expression_system_taxid: 9606. Rift valley fever virus. Rvfv. Organism_taxid: 11588. Expressed in: insect cell expression vector ptie1. Expression_system_taxid: 266783
|
|
Resolution:
|
|
|
2.41Å
|
R-factor:
|
0.197
|
R-free:
|
0.246
|
|
|
Authors:
|
|
Q.H.Wang,Y.Wu,F.Gao,J.X.Qi,G.F.Gao
|
|
Key ref:
|
|
Q.Wang
et al.
(2019).
Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus.
Nat Microbiol,
4,
1231-1241.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
13-Sep-18
|
Release date:
|
10-Apr-19
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Nat Microbiol
4:1231-1241
(2019)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus.
|
|
Q.Wang,
T.Ma,
Y.Wu,
Z.Chen,
H.Zeng,
Z.Tong,
F.Gao,
J.Qi,
Z.Zhao,
Y.Chai,
H.Yang,
G.Wong,
Y.Bi,
L.Wu,
R.Shi,
M.Yang,
J.Song,
H.Jiang,
Z.An,
J.Wang,
T.D.Yilma,
Y.Shi,
W.J.Liu,
M.Liang,
C.Qin,
G.F.Gao,
J.Yan.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes
substantial morbidity and mortality in livestock and humans. To date, there are
no licensed human vaccines or therapeutics available. Here, we report the
isolation of monoclonal antibodies from a convalescent patient, targeting the
RVFV envelope proteins Gn and Gc. The Gn-specific monoclonal antibodies
exhibited much higher neutralizing activities in vitro and protection efficacies
in mice against RVFV infection, compared to the Gc-specific monoclonal
antibodies. The Gn monoclonal antibodies were found to interfere with soluble Gn
binding to cells and prevent infection by blocking the attachment of virions to
host cells. Structural analysis of Gn complexed with four Gn-specific monoclonal
antibodies resulted in the definition of three antigenic patches (A, B and C) on
Gn domain I. Both patches A and B are major neutralizing epitopes. Our results
highlight the potential of antibody-based therapeutics and provide a
structure-based rationale for designing vaccines against RVFV.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
| | |
Links
